Investor ADAR1 Capital Management, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by ADAR1 Capital Management, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-21 13D/A KROS / Keros Therapeutics, Inc. 5,390,964 5,389,264
2025-08-14 13G/A IBIO / iBio, Inc. 1,095,967 1,794,055
2025-08-14 13G/A IKT / Inhibikase Therapeutics, Inc. 6,994,246 7,737,694
2025-08-14 13G PRTA / Prothena Corporation plc 3,375,009
2025-08-14 13G BIOA / BioAge Labs, Inc. 1,937,123
2025-08-14 13G/A KPRX / Kiora Pharmaceuticals, Inc. 315,103 365,179
2025-08-14 13G/A CLRB / Cellectar Biosciences, Inc. 3,684,708 2,962
2025-05-15 13G/A ACST / Grace Therapeutics, Inc. 1,029,997 1,502,143
2025-05-12 13D/A KROS / Keros Therapeutics, Inc. 5,390,964 5,390,964
2025-05-08 13D/A KROS / Keros Therapeutics, Inc. 5,390,964 5,390,964
2025-04-28 13D/A KROS / Keros Therapeutics, Inc. 5,390,964 5,390,964
2025-04-11 13D KROS / Keros Therapeutics, Inc. 5,390,964
2025-02-14 13G/A IBIO / iBio, Inc. 966,298 1,095,967
2025-02-14 13G/A KALA / KALA BIO, Inc. 480,431 298,955
2025-02-14 13G IKT / Inhibikase Therapeutics, Inc. 6,994,246
2025-02-14 13G/A ZURA / Zura Bio Limited 3,332,835 2,077,251
2024-11-14 13G/A IBIO / iBio, Inc. 966,298
2024-11-14 13G KALA / KALA BIO, Inc. 480,431
2024-11-14 13G ZURA / Zura Bio Limited 3,332,835
2024-11-14 13G/A CLRB / Cellectar Biosciences, Inc. 3,684,708
2024-11-14 13G KPRX / Kiora Pharmaceuticals, Inc. 315,103
2024-11-14 13G PCSC / Perceptive Capital Solutions Corp 750,000
2024-11-14 13G/A ACST / Grace Therapeutics, Inc. 959,571 1,029,997
2024-08-01 13G PIRS / Pieris Pharmaceuticals, Inc. 138,641
2024-07-10 13G ACST / Grace Therapeutics, Inc. 959,571